The partnership aims to further enhance healthcare and innovation in the Kingdom as part of Saudi Vision 2030
Coralville, Iowa. February 1, 2023 –Digital Diagnostics – maker of LumineticsCore™ (formerly known as IDx-DR), the first-ever FDA-cleared, fully autonomous AI system for the diagnosis of diabetic retinopathy – announced today a strategic partnership with Tamer Healthcare – an integrated healthcare and wellness firm with more than 100 years of established business in the Kingdom of Saudi Arabia – to further enhance healthcare and innovation in the Kingdom of Saudi Arabia.
The strategic partnership initially centers on the distribution of Digital Diagnostics flagship product, LumineticsCore (formerly known as IDx-DR), for the detection of diabetic retinopathy (including macular edema) with plans for future artificial intelligence (AI) technology development and expansion. The Saudi Arabian population has one of the most acute needs for such innovative technology, in order to save the vision of over 8 million people with diabetes in the Kingdom of Saudi Arabia.
Tamer Healthcare will also work together with Digital Diagnostics to deploy additional AI healthcare applications that are created in conjunction with the Saudi Localization Plan.
“This long-term partnership aims to further enhance healthcare and innovation in the Kingdom as part of Saudi Vision 2030,” said Dana Cooney, VP of International Sales at Digital Diagnostics. “Most importantly, this partnership signifies Digital Diagnostics’ commitment to foster investment in the Kingdom by developing innovative healthcare solutions rooted in AI that create access to affordable and high-quality care for the people of the Kingdom of Saudi Arabia.”
“We look forward to leveraging this partnership to facilitate the advancement of healthcare innovation for the benefit of the nation,” said Dr. Yasser Khattab, CEO of Tamer Healthcare. “Deploying new technology in tandem with a company that has successfully developed and deployed this type of system will help expedite the process in the Kingdom and foster continued local innovation and technology solutions.”
About Digital Diagnostics Inc.
Digital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to transform the quality, accessibility, equity, and affordability of global healthcare through the application of technology in the medical diagnosis and treatment process. The company, originally founded by Michael Abramoff, MD, PhD, a neuroscientist, practicing fellowship-trained retina specialist, and computer engineer, is led in partnership with co-founders John Bertrand and Seth Rainford.
Digital Diagnostics is paving the way for autonomous and assistive AI diagnosis to become a new standard of care, contributing to democratizing healthcare and closing care gaps. The company works closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of autonomous AI. Digital Diagnostics LumineticsCore (formerly known as IDx-DR) system does not replace a full – comprehensive seven-point – eye exam. For more information and the latest news follow: https://www.digitaldiagnostics.com/
About Tamer Group
Tamer Group is an integrated healthcare and wellness Group in Saudi Arabia, the Middle East and North African region, offering a portfolio of products and services that contribute to personal wellness and public health. Today, the full extent of the company’s manufacturing and distribution services includes pharmaceuticals and vaccines, medical devices, nutrition and baby health, as well as a digital platform, e-commerce and logistics capabilities. Tamer Group has over 4,000 employees and is owned by the third generation of the family, run with a board of diverse external members embracing full corporate governance and stewardship. For more information: https://www.tamergroup.com.
Digital Diagnostics Media Contact:
Jacque Engle
engle@digitaldiagnostics.com
610-761-1886
Tamer Group Media Contact:
Abdullah Abutaleb
abdullah.abutaleb@tamergroup.com
T +96612 644 0099 Ext: 1114